A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
about
Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety AssessmentThe role of concentration-effect relationships in the assessment of QTc interval prolongationParameter Identifiability of Fundamental Pharmacodynamic ModelsPredicting QTc Prolongation in Man From Only In Vitro Data.The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variabilityModel-based evaluation of drug-induced QTc prolongation for compounds in early development.Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarialsPharmacogenetics of Drug-Induced QT Interval Prolongation: An UpdateAssessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional studyIdentifying the translational gap in the evaluation of drug-induced QTc interval prolongation.From pharmacokinetics to therapeutics.Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing riskDrug-induced QT-interval prolongation: considerations for clinicians.Predicting QRS and PR interval prolongations in humans using nonclinical data.Translating QT interval prolongation from conscious dogs to humans.Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study.Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development.Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.Pharmacokinetic/pharmacodynamic modeling of cardiac toxicity in human acute overdoses: utility and limitationsNoninvasive assessment of dofetilide plasma concentration using a deep learning (neural network) analysis of the surface electrocardiogram: A proof of concept study
P2860
Q26801610-C01EED86-01CE-4C26-AA07-04510CAF6540Q26866417-B764C96D-496F-4C33-8DA3-62BCB3694040Q30830719-B5A0D825-F8D7-4506-A9D5-CDCAB7E36160Q30843780-4A26C92D-5FCF-4660-9D94-2E27C825CF5EQ30854543-17B7B407-B7B0-4C96-8FFA-97D672169D70Q33560293-D0821FAE-9F7D-45E9-8D2C-D97C4A6F2096Q34574831-E6036836-DEDC-4D19-9983-CB910A9EA74EQ34953730-2336F651-55C1-405C-B8A1-92A136B854FEQ36016439-F4D41900-A198-4C36-B411-8F50FE3E93CAQ36018689-BA1F5009-DC34-4E75-A33D-577170D1276CQ36084069-AD872D2B-366C-4F64-B480-F86F65354904Q36400366-774EE7A7-A646-4F37-A3C9-33941E4A2C48Q37156281-B66C3F36-57E7-4DA1-A23B-ECF23E4E3641Q37369309-510A7853-2A1E-40DE-82BA-C496D910ACF4Q37550564-3BCB6B1B-46CE-4A9A-9C5D-E3070C408BFFQ37579944-B05A39E1-1C04-4C89-B93D-E34AAC12FD57Q37604434-2EC9A264-6FA9-48AA-9675-50F5CA08EEFCQ37689202-2F6DAC15-D486-4E42-BC9B-0C557C609ED8Q37767425-867FFF44-8F04-467B-9E1B-A5A34F2DCE51Q38694637-72E8E594-611E-42C3-94BF-B781F4D4A53FQ39404396-038090D2-4486-4FA4-84DE-B250D82C9D89Q45087131-B5D4F6DE-7E4B-4199-807B-AECFE44F203FQ46686425-8F13962F-ABA8-418F-8EC0-4700E8595BDAQ47135264-C2927681-F20D-4FA5-8DC8-E08C59521D7EQ51505796-9D7442AB-6DE4-4BCF-8788-4C7F2EA2DC2AQ51908345-4708A5C8-B6D3-45C4-B776-00130F529B1CQ57016826-B3491BA0-D5C3-42F8-9433-A98AEE04965BQ58723630-D342A93A-A9FD-443D-A948-6649F72AA8D6
P2860
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@ast
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@en
type
label
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@ast
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@en
prefLabel
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@ast
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@en
P2093
P1476
A pharmacokinetic-pharmacodyna ...... gene current inhibition data.
@en
P2093
Daniël M Jonker
Derek Leishman
E Niclas Jonsson
Leslie A Kenna
Peter A Milligan
Rob Wallis
P304
P356
10.1016/J.CLPT.2005.02.004
P407
P577
2005-06-01T00:00:00Z